Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ASP2138 |
Synonyms | |
Therapy Description |
ASP2138 is a bispecific antibody that targets Claudin 18.2 (CLDN18.2) expressed on tumor cells and CD3 on T-cells, which potentially leads to cytotoxic killing of tumor cells expressing CLDN18.2, enhanced antitumor immune response, and inhibition of tumor growth (Cancer Res (2023) 83 (7_Supplement): 2962). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ASP2138 | ASP-2138|ASP 2138 | CD3 Antibody 99 CLDN18.2 Antibody 19 | ASP2138 is a bispecific antibody that targets Claudin 18.2 (CLDN18.2) expressed on tumor cells and CD3 on T-cells, which potentially leads to cytotoxic killing of tumor cells expressing CLDN18.2, enhanced antitumor immune response, and inhibition of tumor growth (Cancer Res (2023) 83 (7_Supplement): 2962). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05365581 | Phase I | ASP2138 + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin ASP2138 + Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab ASP2138 + Paclitaxel + Ramucirumab ASP2138 | A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer | Recruiting | USA | ITA | FRA | 3 |